Last reviewed · How we verify
Phase 1 Evaluation of H1 Influenza Vaccine Delivered by MIMIX MAP
A Phase 1, Randomized, Rater and Participant Blinded Placebo Controlled Study to Evaluate the Safety, Reactogenicity, Tolerability and Immunogenicity of a Standard and a Fractional Dose of H1 Influenza Vaccine Delivered by VX-103 (a MIMIX Microneedle Array Patch (MAP) System) in Healthy Adults ≥18-39 Years of Age
Details
| Lead sponsor | Vaxess Technologies |
|---|---|
| Phase | PHASE1 |
| Status | COMPLETED |
| Enrolment | 45 |
| Start date | Sat Jul 02 2022 00:00:00 GMT+0000 (Coordinated Universal Time) |
| Completion | Mon Mar 13 2023 00:00:00 GMT+0000 (Coordinated Universal Time) |
Conditions
- Influenza
Interventions
- H1 influenza antigen
Countries
Canada